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Background: Pancreatic ductal adenocarcinoma (PDA) is one of the most aggressive malignancies with marked
resistance to chemo- and radiotherapy. PDA-cancer stem cells (CSCs) are not targeted by current therapies and may
be a reason for poor prognosis. Studies indicate that diets rich in cabbage, broccoli, and cauliflower offer cancer
preventative and therapeutic benefits. Recent experimental studies have confirmed these findings and demonstrated
that isothiocyanate, sulforaphane, and the polyphenol, quercetin, effectively reduced tumor growth and enhanced the
sensitivity of the cancer cells to current chemotherapeutics. The aim of the present study is to test the feasibility of a
randomized controlled trial on the application of freeze-dried broccoli sprouts in patients with advanced PDA.
Methods and study design: The study is designed as a prospective randomized, double-blinded pilot trial with a
treatment and a placebo-controlled arm in a single center setting. A total number of forty patients (18 years or older)
in two parallel groups with advanced, surgically non-resectable PDA under palliative chemotherapy are planned for
recruitment. Patients in the treatment group will receive fifteen capsules of the study substance per day (90 mg of
active sulforaphane) during the chemotherapy treatment course. Patients in the placebo group will receive the same
capsule size and portion distribution with inactive substances (mainly methylcellulose). The follow-up duration is one
year. Feasibility of the study substance, adverse effects, and patient compliance, as well as levels of serum tumor
markers (CEA, CA 19-9), quality of life, and patient overall survival rates will be assessed at defined points of time.
Discussion: The POUDER trial is expected to transfer promising experimental and epidemiological data into a
clinical pilot study to assess the effectiveness of broccoli sprout extracts in the treatment of advanced PDA. The
study objectives will provide data on the clinical feasibility and acceptability of a supportive treatment option
accompanying palliative chemotherapy. Based on these results, future clinical studies to create further evidence in
this field are possible.
Trial registration: The POUDER trial has been registered at ClinicalTrials.gov with an ID NCT01879878 and WHO
with an ID U1111-1144-2013 on June 13th 2013.
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Pancreatic ductal adenocarcinoma (PDA) is the fourth
most common cause of cancer-related deaths worldwide.
It is one of the most aggressive and lethal malignancies,
with a 5-year survival rate of 6% in Europe and the United
States, and a median survival time of 4 to 6 months [1-3].* Correspondence: i.herr@dkfz.de; peter.schemmer@med.uni-heidelberg.de
†Equal contributors
Department of General and Transplant Surgery, University Hospital
Heidelberg, Im Neuenheimer Feld 110, 69120 Heidelberg, Germany
© 2014 Lozanovski et al.; licensee BioMed Cen
Creative Commons Attribution License (http:/
distribution, and reproduction in any medium
Domain Dedication waiver (http://creativecom
article, unless otherwise stated.With an incidence proportionally correlated to age [1],
the numbers of estimated new cases and PDA-related
deaths for 2013 in the United States alone are 45,220 and
38,460, respectively [4]. Despite standardization and ad-
vances in surgical and systemic treatment options, cura-
tive surgical intervention is possible in only 20% of the
patients [5], due to the cancer’s initial asymptomatic
course. Most patients present with an advanced stage
of disease and can therefore only be treated in a pallia-
tive intention, which explains the nearly similar rates oftral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Table 1 Trial inclusion and exclusion criteria
Inclusion criteria Exclusion criteria









aPatients who receive surgical exploration, intraoperative biopsy, and/or
palliative bypass interventions (bileodigestive anastomosis and/or
gastroenterostomy because of preoperative cholestasis or impaired gastric
emptying due to a tumor-mass effect) will be included in this trial. PDA,
pancreatic ductal adenocarcinoma.
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aberrations, intense desmoplastic stroma reaction, and
hypoxia are some of the factors that presumably cause
the poor outcome [7].
Recent research data strongly suggest that cancer is a
stem cell disease [8,9]. The small subpopulation of can-
cer stem cells (CSCs) within the tumor mass is thought
to survive during conventional cytotoxic therapy due to
its defense and survival mechanisms [10]. CSCs are be-
lieved to be capable of self-renewal and differentiation,
thereby generating a heterogeneous cell population of
the original tumor [8,11,12]. In addition, it has been pro-
posed that CSCs mediate uncontrollable growth, therapy
resistance, cell invasion, and metastasis [13]. Markers for
CSCs have been identified in various tumor entities, in-
cluding PDA, and selected marker-positive cell fractions
are able to reconstitute the original tumor in immuno-
deficient mice [14].
In a review published in 2007, the American Institute for
Cancer Research (AICR) drew attention to the benefits
of increased cabbage consumption in PDA patients [15].
These results were not restricted to the pancreas, as two
recent epidemiological, prospective nutrient studies dem-
onstrated significant inhibition of metastases seeding in pa-
tients with prostate cancer [16,17]. Kirsh, et al. observed
the significantly decreased risk of extra-prostatic manifest-
ation of prostate cancer (stage III or IV tumors) correlated
with an increase in the consumption of cruciferous vegeta-
bles, in particular broccoli which is rich in sulforaphane
and quercetin (P = 0,02) [16]. The benefits inferred by sul-
foraphane, which is derived from mustard oil, and its in-
active glycoside precursor, glucoraphanin (present in high
concentrations in broccoli and its sprouts), have been thor-
oughly investigated [18,19]. Sulforaphane is believed to tar-
get CSCs through the downregulation of NF-κB [18]. This
observation was first discovered in PDA and has also been
confirmed for breast and prostate cancer [20,21]. Conse-
quently, these substances may serve as an alternative treat-
ment option for PDA; by exhausting pancreatic CSCs, the
tumor sensitivity to chemotherapeutics, such as sorafenib,
gemcitabine, cisplatin, doxorubicin, and 5-fluorouracil,
may be significantly improved [20,22,23].
Trial rationale
Epidemiological and animal studies in various cancer en-
tities [15-17,20,24-29] clearly demonstrate that broccoli
sprouts, rich in sulforaphane, have a tumor-suppressive
potential [18]. However, to date there has been no rou-
tine clinical application of broccoli sprouts or their iso-
lated phytochemical substances. The aim of this pilot
study is to evaluate, for the first time, the feasibility and
clinical impact of a daily application of encapsulated,
freeze-dried broccoli sprouts in PDA patients in a palliative
setting as a chemotherapy-supporting agent. The results ofthe study could consequently serve as the rationale for the
design of further clinical trials.
Methods/Design
The ethics committee of the University of Heidelberg
has approved the POUDER trial as a monocentric, pro-
spective, randomized, placebo-controlled clinical pilot
study with two parallel groups (placebo versus verum) and
provided the trial ethical approval (reference S-347/2009).
Forty eligible patients receiving palliative chemotherapy,
who meet the inclusion criteria (Table 1), with advanced,
non-resectable PDA treated at the European Pancreas
Center in Heidelberg, will be enrolled after signing in-
formed consent. Approximately 15 to 20 PDA patients
who meet the study inclusion criteria are treated in the
outpatient department of the European Pancreas Center
per month. Therefore, a short recruitment period of 3 to
4 months is expected. Exclusion criteria are a known in-
tolerance to broccoli or its ingredients, impaired mental
status, language problems, or a refusal of participation.
Due to the nutrition supplemental character of the trial,
sufficient oral intake is a prerequisite for inclusion in the
study that is, the patients should not have symptoms or
signs of indigestion or problems with the passage of food
(nausea, vomitus, presence of nasogastric tube) (Table 1).
Trial objectives
The objective of this pilot trial is to evaluate the feasibil-
ity of nutritional supplements rich in sulforaphane and
quercetin, administered via encapsulated, freeze-dried
broccoli sprouts, in patients with advanced pancreatic
cancer undergoing treatment with palliative chemother-
apy. In this context, given that patients are supposed to
take 15 capsules per day, the principal objective of this
trial is to test if the daily intake is possible. In order to
achieve the effective sulforaphane dose as extrapolated
from our previous animal experiments, the capsules
should be taken all 15 at once, however with an accept-
able pause of few minutes in between.
Lozanovski et al. Trials 2014, 15:204 Page 3 of 8
http://www.trialsjournal.com/content/15/1/204Outcome measures
Serum levels of the pancreatic tumor markers carbohy-
drate antigen 19-9 (CA19-9) and carcinoembryonic antigen
(CEA), and routinely performed cross-sectional imaging
(computed tomography or magnetic resonance imaging),
will be monitored and assessed as parameters for evaluat-
ing disease status. Staging examinations will take place
every three months after study inclusion during the treat-
ment course with cytoreductive chemotherapy (Figure 1).Figure 1 Flow chart of the POUDER-Trial. PDA, pancreatic ductal adeno
computed tomography; MRI, magnetic resonance imaging. Tumor markersThe total concentration of isothiocyanates (sulforaphane)
in urine will serve as a monitoring parameter for the evalu-
ation of patient compliance. Additionally, the overall sur-
vival rate will be documented.
To evaluate the quality of life of the study participants,
questionnaires (European Organisation for Research and
Treatment of Cancer (EORTC) Quality of Life Question-
naires (QLQ-PAN26, QLQ-C30) will be completed at
every follow-up visit (3, 6, and 12 months after patientcarcinoma: AE, adverse event: SAE, serious adverse event: CT,
: CEA and CA 19-9.
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kept to document the regular intake and amount of the
test substances, and any observable side effects (adverse
or otherwise) (Figure 1). If outcome differences between
the verum and the placebo groups are detected after
completion of the POUDER trial, statistical analyses will
be performed in order to generate a hypothesis for a
confirmatory trial on this topic.
Trial interventions
Patients will be given 15 capsules of either verum or pla-
cebo per day during the chemotherapy treatment course.
The follow-up duration is one year. The daily dose of
the nutritional supplement for the verum group contains
90 mg of active sulforaphane distributed over 15 cap-
sules, each of which contains 400 mg of broccoli sprout
grain (6 mg of sulforaphane per capsule). In contrast,
the placebo capsules consist of 400 mg of inactive sub-
stances (mainly methylcellulose) with an identical cap-
sule size and intake protocol. Study substances (for the
verum and placebo groups) will be produced, labeled,
and packed by Food-Service, Deiters & Florin GmbH
(Hamburg, Germany). The guidelines for Good Manu-
facturing Practice (GMP) have been adhered to at all
times. Participants will be provided with a 3-month sup-
ply of capsules at every visit (Figure 1).
Urine samples will be collected one week and one and
six months after randomization to analyze the concen-
tration of the isothiocyanates (Figure 1). The analysis will
be done from frozen aliquots using 1,2-benzenedithiol
cyclocondensation as described by Shapiro et al. [30] and
assessed by high performance liquid chromatography
(HPLC). The urine concentration of the degradation
products of sulforaphane is used to evaluate the bio-
availability of the substance after oral ingestion, as well
as patient compliance. In general, sulforaphane levels
are significantly higher than those of its inactive precur-
sor, glucoraphanin, thanks in part to the nature of the
precursor itself. Both sulforaphane and glucoraphanin
are present in known concentrations in the adminis-
tered broccoli sprouts. However, due to its slower clear-
ance from the body [31], glucoraphanin acts as a depot
for the active substance. This, in turn, prolongs the
half-life of sulforaphane in the blood. By using HPLC,
the conversion of the precursor to the active substance
in the body can be measured and monitored.
Biochemical analysis of serum tumor markers will take
place during the first visit and for all subsequent visits,
scheduled at 3-month intervals, until the end of the
follow-up period. Diagnostic imaging (CT/MRI scans)
will be routinely performed during the oncological fol-
low up of the patients. If the findings of the imaging
diagnostic are available, they will be included as moni-
toring parameters and, together with the tumor markers,will provide insight into the status of the disease. The
last visit will be scheduled one year after the beginning
of the trial and will serve to investigate the clinical status
of the patient, as well as to compile all efficacy and
safety data.
Randomization and blinding
A 1:1 randomization will be performed and patients will
be assigned with a randomization number. In case there
are dropouts, these patients will be replaced and the
new patients will be assigned in an identical manner. If a
patient drops out of the study at month 6 due to his/her
own decision, the patient data will be removed from the
trial completely, including any data generated prior to
the withdrawal. If a patient passes away during the first
6 months, the data will be used. If the urine probes re-
veal that a patient from the broccoli sprouts group did
not consume the broccoli sprouts daily or if a patient
from the placebo group had a high dietary intake of iso-
thiocyanates, the data from these patients will not be
used, but the patient will be replaced by a new patient,
even if a patient drops out between months 9 to 12. This
case will extend the duration of the study. Randomly
generated numbers will be allocated to the two groups
in balanced permuted blocks using a number generator
(validated software, SAS). In order to avoid any possibil-
ity of predicting the group allocation, the length of the
blocks will be fixed in a separate document and this in-
formation will be withheld from the study site. A data
sheet that links the group allocation with the randomized
number of the patient will be sealed in pre-produced, non
transparent envelopes labeled with the arbitrary patient
numbers and these envelopes will be used in consecutive
order. In order to be able to perform a retrospective con-
trol of the compliance to randomization, basic patient
data, including the day on which the patient’s number was
assigned, will be noted on the data sheet. After completing
the trial, all unopened envelopes will be delivered to the
data management center for comparison to the allocated,
randomized patient numbers and examination and evalu-
ation of the thoroughness of the trial.
The investigators, patients, and assessors of the
POUDER trial will be blind to the patients’ study treatment
courses. The principal investigator (PI) will be provided
with a set of sealed envelopes containing information on
patients’ trial drugs, one for each patient number. These
envelopes are to be opened only under imperative circum-
stances (medical indication to know the substance in use
by the subject).
Data management and statistical analysis
The trial investigator or a designated representative (sub-
investigator) will document all data acquired during the
trial in a case report form (CRF) on the day of the routine
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inferred. Upon completion, all CRFs must be officially
reviewed and signed by either the investigator named in
the trial protocol or by a designated sub-investigator. In
order to assure the highest data quality and accurate trans-
fer from the CRF to the database, a double data-entry
method will be performed. After completing the trial, the
PI will retain the original CRFs.
Totality, validity, and plausibility of the data will be ex-
amined by validating programs that will generate queries
that must be clarified by the investigator. All findings,
both clinical and overall survival, imaging of disease stages,
quality of life, and biochemical analyses will be noted in
the subject’s CRF.
As this is a pilot study, no sample size calculation was
performed. A sample size of 20 patients per study group
has been deemed sufficient for the study objectives. The
sample size of 20 patients per group is speculative at this
time and it is based on comparable patient numbers used
in similar ongoing and recently completed patient studies
with broccoli sprout extracts. For example, the Pittsburgh
pilot study evaluating sulforaphane in atypical nevi-
precursor lesions enrolled 18 patients (clinicaltrials.gov/
ct2/show/NCT01568996?term=NCT01568996&rank=1)
and another study performed at OHSU Knight Cancer
Institute for examination of sulforaphane in treating pa-
tients with recurrent prostate cancer (clinicaltrials.gov/ct2/
show/record/NCT01228084?term=sulforaphane&rank=1)
enrolled 20 patients.
Depending on data characteristics, descriptive statistics
of the monitored parameters will be presented as mean
values and SD or median values and IQR. Descriptive
P-values of the t-test or the Mann-Whitney U-test compar-
ing the treatment groups will be given, together with the
corresponding 95% CI. Categorical parameters will be pre-
sented as relative and absolute frequencies, and compari-
sons will be performed using the Fisher exact test.
Survival curves will be constructed using the Kaplan-
Meier estimator. The descriptive P-value of the log-rank
test will be used to compare the survival curves of the
treatment groups. Estimated median survival times and
the one-year survival rates with 95% CI will be given.
SAS software (Release 9.1, SAS Institute, Inc. Cary,
NC, USA) and Microsoft Office Excel 97® (Redmond,
Washington, USA) will be used for the statistical analysis
and graphical presentations.
Adverse and serious adverse events
Any manifestation of symptoms or conditions, labora-
tory parameter alteration, or recurrence or aggravation
of existing co-morbidity that correlate with the use of an
investigational or medicinal substance or product consti-
tutes an adverse event (AE). A serious adverse event
(SAE) is defined as an AE that is life threatening andnecessitates hospitalization and/or prolonged medical
treatment until stabilization. The occurrence of all events
that can be classified as adverse will be recorded and
its clinical course will be followed until resolution and
stabilization. Events associated with the primary diagno-
sis, the surgical procedure itself, or complications related
to the palliative chemotherapy will not be registered as
SAEs unless deemed so by the investigator. All SAEs
will be documented and reported to the PI (author PS)
within 24 hours or during the following calendar work-
ing day, at the latest. The PI will then report the newly
documented SAEs to the ethics committee and the in-
vestigators. Apart from meteorism, which is a common
phenomenon associated with cabbage, a very low risk for
AEs is expected during this trial.
Assurance of quality
The principles of the International Conference on
Harmonisation-Good Clinical Practice (ICH-GCP) guide-
lines [32], the regulations of the Declaration of Helsinki,
[33] and local legal and regulatory requirements will be ad-
hered to at all times during the trial period. Medical confi-
dentiality and accordance with the German Federal Data
Protection Act will also be observed [34].
Discussion
Since ancient times, cabbages and other extracts of the
botanic family Brassicacea have been used as natural an-
tibiotics and key components of antiviral drugs and anti-
mycotics. Members of the Brassicacea family contain
glycosides that trigger the release of mustard oils after
enzymatical hydrolyzation, in case of physical damage
of the plant cells. These mustard oils offer protection
against microorganisms and fungi. To date, the bioactive
function of more than 120 different mustard oils have
been documented [35].
With regard to numerous worldwide studies, an in-
verse relationship between consumption of cruciferous
vegetables (including members of the Brassicacea family)
and the risk of neoplastic diseases has been observed,
namely in colorectal, gastric, lung, breast, prostate, bladder,
and endometrial cancers [18,19]. The bioactive phyto-
chemicals, sulforaphane and quercetin have been shown to
be potent substances that possess chemopreventive and
therapeutic properties beneficial in cancers of the intestine,
breast [28,29], prostate [17], and pancreas [20]. Sulforaph-
ane, and its inactive glycoside precursor, glucoraphanin,
are present in high concentrations in broccoli and its
sprouts [18,19]. Sulforaphane is a potent antioxidant that
indirectly eliminates free radicals; by increasing the con-
centration of glutathione, sulforaphane inhibits the for-
mation and accumulation of carcinogen-induced DNA
adducts [18,36], a finding that has been demonstrated in
several animal studies [25,26]. Furthermore, sulforaphane
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based on recent experimental studies in which the com-
pound has been shown to target CSCs in models of pan-
creatic, breast, and prostate cancer [20,21]. In pancreatic
cancer, sulforaphane was shown to exhibit its anti-CSC ef-
fect through the downregulation of NF-κB activity, which
is usually enhanced in active CSCs [18]. Consequently,
sulforaphane might be effective in overcoming the resist-
ance of pancreatic cancer cells to chemotherapy, as under-
lined by recent experimental studies. These studies show
that sulforaphane increases the responsiveness of pancre-
atic CSCs to sorafenib, gemcitabine, cisplatin, doxorubicin,
and 5-fluorouracil [20,22,23].
Another bioactive agent is quercetin, a polyphenol fla-
vonoid commonly found in apples, berries, red grapes,
onions, and broccoli, [37] with antioxidant, anticarcino-
genic, anti-inflammatory and cardioprotective activities
[38,39]. Recent reports describe the possible use of quer-
cetin to inhibit the self-renewal and therapy resist-
ance of pancreatic CSCs by affecting clonogenicity,
spheroid formation, and aldehyde dehydrogenase iso-
form 1 (ALDH1) activity, as well as blocking the signaling
pathways involved in apoptosis resistance, proliferation,
angiogenesis, NF-κB activity, and epithelial-mesenchymal
transition (EMT) [27]. It is most effective in combination
with sulforaphane both in vitro and in vivo, without
inducing toxic side effects in mice [27]. These findings
emphasize the need for dietary intervention studies to elu-
cidate the therapeutic effects of vegetables rich in sulfo-
raphane and quercetin for more successful treatment of
therapy-resistant PDA.
Since 2012 a pilot study has been evaluating the dose-
dependent effects of broccoli sprout extract on atyp-
ical nevi, as precursor lesions and malignant melan-
oma (clinicaltials.gov identifier: NCT01568996) in an
18-patient collective. Two other ongoing pilot studies are
examining the preoperative administration of broccoli
sprout extract in patients with transitional cell bladder can-
cer undergoing surgery (NLM identifier: NCT01108003)
and the additive intake of broccoli sprout extract in
patients with recurrent prostate cancer (clinicaltrials.gov
identifier: NCT01228084).
From the available studies, it can be noted that there is
a positive correlation between the consumption of broc-
coli and an increased efficacy of chemotherapy [27,40].
However, to date this is not based on high-level evidence
trials. The POUDER trial will not interfere with any pal-
liative chemotherapy or targeted therapy as these sub-
stances typically do not require any food restrictions.
Consequently, patients who participate in PDA trials can
simultaneously participate in a broccoli nutritional study.
However, compounding effects of the intake of broccoli
sprouts might have an influence on the results of any par-
allel trial due to the potential benefit of their application.The present trial has to be regarded as a test of feasibility.
Participation in other treatment schemes - regardless of
whether or not standard or study substances are applied -
was not defined as a contraindication for inclusion. As pa-
tients suffering from tumor diseases are often encouraged
to make healthy changes in their lifestyle, other phy-
totherapies may be expected. Yet, the effects of the chosen
high dosage of the broccoli sprout extract will probably
overpower the effects of any other nutritional substance.
A possible side effect of high broccoli sprout intake
may be meteorism, which is a common phenomenon
associated with cabbage consumption. Other effects in-
clude the prominence of the rotten-egg odor. During the
metabolic breakdown of cabbage in the digestive tract,
sulfur in the glucosinolates [41] is converted into the
rotten-egg chemical, hydrogen sulfide, by gut bacteria.
These potential side effects may be uncomfortable, but
are considered to be insignificant in the overall context
of a promising therapy for an advanced tumor disease.
With regard to sulforaphane, its modus operandi is be-
lieved to be as an indirect antioxidant that helps to pro-
tect healthy cells from oxidative damage and reduce the
short- and long-term harmful effects of cancer treatment
[42]. However, concern has been raised that antioxidant
supplements may also protect tumor cells during chemo-
therapy, thereby compromising treatment efficacy [42,43].
This has resulted in controversy over the guidelines for the
use of vitamin supplements during cancer treatment. This
issue was examined in an experimental human PDA xeno-
graft model in mice. In this setup, sulforaphane did not
protect tumor cells; instead, it increased the effect of gem-
citabine, cisplatin, doxorubicin, 5-fluorouracil, sorafenib,
and TRAIL [20,22,23,27].
In closing, the POUDER trial is the first clinical pilot
trial to test the feasibility of an intake of freeze-dried
broccoli sprouts as an additive of palliative chemotherapy
in surgically non-resectable, advanced pancreatic cancer.
Depending on the results of this pilot trial, a hypothesis for
a confirmatory trial in the field will be generated and a
consecutive RCT is planned.
Trial status
The POUDER trial has been designed as a single center
pilot randomized controlled trial (RCT). The initiation
took place at the Department of Surgery, University of
Heidelberg in December 2013 after approval by the local
ethical committee.
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